4-色满酮芳环Mannich碱类化合物的合成及其抗血小板聚集活性研究

4-色满酮类化合物和色酮类化合物具有广泛的生物活性。笔者曾发现4-色满酮3位Mannich碱类化合物具有显著的抗血小板聚集活性,为了考察在4-色满酮的3-位Mannich碱类化合物中3-位胺甲基侧链是否为加强活性的必需基团,为确定其药效构象提供信息,笔者设计合成了4种4-色满酮芳环Mannich碱类化合物,同时又合成了3种色酮芳环Mannich碱类化合物。所合成的目标化合物均未见文献报道,其组成和结构经红外光谱、质谱和核磁共振氢谱确认。采用Born's比浊法对目标化合物进行了抗血小板聚集活性的体外筛选。实验结果表明,目标化合物对ADP和胶原诱导的家兔血小板聚集均具有显著的体外抑制活性。     

利奈唑酮的合成

以3-氟-4-（4-吗啉基）苯胺和（S）-{N-[3-（3＇-氟-4＇-吗啉基）苯基-2-氧代-5-嗯唑烷基]甲基}乙酰胺为原料合成利奈唑酮,通过调整配料比、使用新溶剂、优化反应条件等,提高了反应收率,降低了生产成本,使该工艺更易于工业化生产。     

呋喃并[3,2-g]色满类化合物的合成及抗肿瘤活性研究

为了发现新型选择性雌激素受体调节剂,以雷洛昔芬为先导化合物,利用生物电子等排原理以及拼合原理,将雷洛昔芬结构中的苯并噻吩环替换成呋喃并[3,2-g]色满骨架,并进行结构优化,考虑到目标化合物合成的可行性等因素,设计出2-芳酰基-3-芳基呋喃并[3,2-g]色满类化合物作为目标化合物。以7-羟基色满为原料,经过酯化反应和Fries重排后得到6-(4-甲氧基苯甲酰基)-7-羟基色满,进而与取代的α-卤代苯乙酮缩合得关键中间体2-芳甲酰基-3-(4-甲氧基苯基)呋喃并[3,2-g]色满,脱甲基后再与不同氯乙基胺类化合物进行Williamson反应得到目标化合物。所有的10个目标化合物均未见文献报道,其结构经ESI-MS和1H NMR确证。采用MTT法对目标化合物体外抗肿瘤活性进行初步筛选,结果表明,目标化合物7d对人乳腺癌细胞MCF-7、人骨肉瘤细胞U2OS-EGFP-4A12G和人卵巢癌细胞SKOV3具有显著的抑制活性,具有进一步研究价值。     

硫杂蒽酮化合物的合成研究

用2,2'-二硫代水杨酸在浓硫酸的催化作用下合成了 O-(硫杂蒽酮-[2]-基)-氧乙酸、2-氯硫杂蒽酮、1-氯-4-羟基硫杂蒽酮以及2-羟基硫杂蒽酮等硫杂蒽酮类化合物.并且通过元素分析、红外光谱、紫外光谱、核磁氧谱、碳谱及差热热重分析等实验方法进行表征.结果表明,所合成的硫杂蒽酮类化合物具有所述的特征结构.     

两种带吡啶基侧臂的新型不对称卟啉的合成与表征

合成了2种带吡啶基侧臂的新型不对称卟啉,5-[4-(乙烯基氧基)苯基]-10,15,20-三[4-((2-(O-吡啶-3基)乙氧基)氧基)苯基]卟啉和其水溶性阳离子卟啉5-[4-(乙烯基氧基)苯基]-10,15,20-三[4-((2-(O-(N-甲基吡啶)-3基)乙氧基)氧基)苯基]卟啉,并通过红外光谱、质谱、核磁共振氢谱、紫外光谱和荧光光谱对其结构进行了表征。     

近期医药中间体专利信息

吡唑并[4，3-d]嘧啶衍生物的制备方法，制备2-腈基联苯衍生物的方法，治疗哮喘、过敏和炎症的化合物及其中间体，用于制备具有5-羟色胺-2受体拮抗作用和α1-阻断作用的化合物的中间体及其制法，用于制备紫杉烷的嗯唑烷中间体，制备胆固醇酯转运蛋白抑制剂的方法，含有5-[4-[2-（N-甲基-N-2吡啶基）氨基]乙氧基]苄基]噻唑烷-2，4-二酮的组合物。[编者按]     

双苯并吡喃酮1，3，4-噁二唑基哒嗪酮衍生物的合成

以DMF为溶剂,碳酸钾为催化剂,2-（2H-苯并吡喃-2-酮-3基）-5-巯基-1,3,4-噁二唑与4,5-二氯-2-苄基-哒嗪-3-酮于125℃反应6 h,合成了4-｛2-[（2H-苯并吡喃）-2-酮]-1,3,4-噁二唑-5-硫醚｝-2-苄基-5-｛2-[（2H-苯并吡喃）-2-酮]-1,3,4-噁二唑-5-硫醚｝哒嗪-3（2H）-酮化合物,收率68.6％,其结构经1H NMR、 IR以及元素分析确证。     

4-色满酮曼尼希碱类化合物的合成及其抗血小板聚集活性

4-色满酮类化合物具有广泛的生物活性。为了考察4-色满酮类化合物的抗血小板聚集活性构效关系,笔者设计合成了10种4-色满酮Mannich碱类化合物,其组成和结构经熔点、红外光谱和核磁共振氢谱确证,其中6个(5d～5g,5i～5j)目标化合物均未见文献报道。采用Born's比浊法对目标化合物进行了抗血小板聚集活性的体外筛选,实验结果表明,目标化合物对二磷酸腺苷(ADP)诱导的家兔血小板聚集均具有显著的体外抑制活性。     

4-苄基-2-[(R)-1-[3,5-二(三氟甲基)苯基]乙氧基]吗啉-3-酮的不对称转化的动态动力学拆分

以4-苄基-2-羟基吗啉-3-酮为原料,经两步反应制备得到一对非对映异构体4-苄基-2-[(R)-1-[3,5-二(三氟甲基)苯基]乙氧基]吗啉-3-酮,然后以叔丁醇钾为碱环境,利用不对称转化的动态动力学拆分,转化为手性纯(R)-4-苄基-2-[(R)-1-[3,5-二(三氟甲基)苯基]乙氧基]吗啉-3-酮。转化后手性产物与非对映异构体的比例为96∶4,在工业化制备神经激肽-1(NK-1)受体阻滞剂阿瑞吡坦过程中有较好的应用价值。     

3-[(4'-羧基)-2'-喹啉基]酚酮的合成及溴代和偶联反应

报道了 Pfitzinger喹啉合成法在酚酮领域中的首次应用。 3-乙酰基酚酮 ( 1 )在氢氧化钾存在下与靛红反应 ,得到了喹啉基取代的酚酮化合物 3- [( 4′-羧基 ) - 2′-喹啉基 ]酚酮 ( 2 ) ;化合物 2经溴化反应得到双溴代产物5 ,7-二溴 - 3- [( 4′-羧基 ) - 2′-喹啉基 ]酚酮 ( 3) ;化合物 2经偶联反应得到 5位偶联产物 5 -苯偶氮基 - 3- [( 4′-羧基 ) -2′-喹啉基 ]酚酮 ( 4)。化合物 2、3、4为尚未见文献报道的新化合物 ,它们的结构经红外光谱、核磁共振谱及元素分析予以证实。     

Biologically-Active Gold(III) Complexes

A review is given of the background to and results of the succesful pharmacological testing of [AuX(2)(damp)] (X = Cl, OAc; damp = 2-Me(2) NCH(2)C(6) H(4)) against a range of microbes, fungi and tumouts, culminating in in vivo xenografts of ZR-1-75. These are the first fully evaluated gold(III) complexes. The activity and reactions of the diacetato-complex bear a resemblance to cisplatin, and some of the relevant chemistry is discussed. Preliminary screening data for C,P-chelated tertiary phosphine derivatives of gold(III) are presented.     

Nitriles in heterocyclic synthesis. Part II: Synthesis and application of pyrano[3,2-h]quinoline sulphonamide derivatives

5-Sulphonamido-8-quinolinol reacts with cinnamonitrile derivatives in the presence of a basic catalyst to give pyrano[3,2-h]quinoline sulphonamide derivatives ( 8_a-d-13_a-d ). The reaction of 8_b, 9_b with some reagents such as acetic anhydride, acetic anhydride/pyridine mixture, formamide and formic acid/formamide mixture gave the fused heterotetracyclic systems pyrimido-[4′, 5′: 6, 5]pyrano[3, 2-h] quinoline sulphonamide derivatives. The structures of all newly synthesized compounds were confirmed by elemental analyses and spectral data. These compounds showed antimicrobial activity against some selected bacteria in vitro.     

Synthesis and radioprotective activity of new organosilicon and germanium compounds

Silathiazolidine and metalladithioacetals (M = Si, Ge) have been prepared by the interaction of dialkyldichloro- or bis(diethylamino)dialkylsilanes and -germanes with 3-[N-(2- thioethyl)]amino-propanamide (WR-2529) and [1-thioethyl-2-(1-naphtylmethyl)]-2- imidazoline. The study of these compounds in the field of chemical radioprotection has shown a notable decrease in the toxicity and a rather large increase in the radioprotective activity of these new derivatives in comparison with the starting organic compounds.     

Oxygen Radical Scavenger Activity, EPR, NMR, Molecular Mechanics and Extended-Hückel Molecular Orbital Investigation of the Bis(Piroxicam)Copper(II) Complex

The oxygen radical scavenger activity (ORSA) of [Cu(II)(Pir)(2)] (HPir = Piroxicam = 4-hydroxy -2- methyl -N-2- pyridyl -2H- 1,2-benzothiazine -3- carboxamide 1,1-dioxide) was determined by chemiluminescence of samples obtained by mixing human neutrophils (from healthy subjects) and [Cu(II)(Pir)(2)(DMF)(2)] (DMF = N,N -dimethylformammide) in DMSO/GLY/PBS (2:1:2, v/v) solution (DMSO = dimethylsulfoxide, GLY = 1,2,3-propantriol, PBS = Dulbecco's buffer salt solution). The ratio of the residual radicals, for the HPir (1.02.10(-4)M) and [Cu(II)(Pir)(2)(DMF)(2)] (1.08.10(-5)M)/HPir (8.01.10-(-5)M) systems was higher than 12 (not stimulated) [excess of piroxicam was added (Cu/Pir molar ratio approximately 1:10) in order to have most of the metal complexed as bischelate]. In contrast, the ratio of residual radicals for the CuCl(2) (1.00.10(-5)M) and [Cu(II)(Pir)(2)(DMF)(2)] (1.08.10(-5)M)/Hpir (8.01.10(-5)M)system was 5. The [Cu(II)(Pir)(2)] compound is therefore a stronger radical scavenger than either HPir or CuCl(2). A molecular mechanics (MM) analysis of the gas phase structures of neutral HPir, its zwitterionic (HPir(+-)) and anionic (Pir(-)) forms, and some Cu(II)-piroxicam complexes based on X-ray structures allowed calculation of force constants. The most stable structure for HPir has a ZZZ conformation similar to that found in the Cu(II) (and Cd(II) complexes) in the solid state as well as in the gas phase. The structure is stabilized by a strong H bond which involves the N(amide)-H and O(enolic) groups. The MM simulation for the [Cu(II)(Pir)(2)(DMF)(2)] complex showed that two high repulsive intramolecular contacts exist between a pyridyl hydrogen atom of one Pir(-) molecule with the O donor of the other ligand. These interactions activate a transition toward a pseudo-tetrahedral geometry, in the case the apical ligands are removed. On refluxing a suspension of [Cu(II)(Pir)(2)(DMF)(2)] in acetone a brown microcystalline solid with the Cu(Pir)(2).0.5DMF stoichiometry was in fact prepared. (13)C spin-lattice relaxation rates of neutral, zwitterionic and anionic piroxicam, in DMSO solution are explained by the thermal equilibrium between the three most stable structures of the three forms, thus confirming the high quality of the force field. The EPR spectrum of [Cu(II)(Pir)(2)(DMF)(2)] (DMSO/GLY, 2:1, v/v, 298 and 110 K) agrees with a N2O2+O2 pseudo-octahedral coordination geometry. The EPR spectrum of [Cu(II)(Pir)(2).0.5DMF agrees with a pseudo-tetrahedral coordination geometry. The parameters extracted from the room temperature spectra of the solution phases are in agreement with the data reported for powder and frozen solutions. The extended-Hückel calculations on minimum energy structures of [Cu(II)(Pir)(2)(DMF)(2)] and [Cu(II)(Pir)(2)] (square planar) revealed that the HOMOs have a relevant character of d(x) (2)-y(2). On the other hand the HOMO of a computer generated structure for [Cu(II)(Pir)(2)] (pseudo-tetrahedral) has a relevant character of d(xy) atomic orbital. A d(xy) orbital is better suited to allow a dpi-ppi interaction to the O(2) (-) anion. Therefore this work shows that the anti-inflammatory activity of piroxicam could be due in part to the formation of [Cu(II)(Pir)(2)] chelates, which can exert a SOD-like activity.     

The anti-inflammatory activity of boron derivatives in rodents

Acyclic amine-carboxyboranes were effective anti-inflammatory agents in mice at 8 mg/kg x 2. These amine-carboxyboranes were more effective than the standard indomethacin at 8 mg/kg x 2, pentoxifylline at 50 mg/kg x 2, and phenylbutazone at 50 mg/kg x 2. The heterocyclic amine derivatives as well as amine-carbamoylboranes, carboalkoxyboranes, and cyanoboranes were generally less active. However, selected aminomethyl-phosphonate-N-cyanoboranes demonstrated greater than 60% reduction of induced inflammation. The boron compounds were also active in the rat induced edema, chronic arthritis, and pleurisy screens, demonstrating activity similar to the standard indomethacin. The compounds were effecive in reducing local pain and decreased the tail flick reflex to pain. The derivatives which demonstrated good anti-inflammatory activity were effective inhibitors of hydrolytic lysosomal, and proteolytic enzyme activities with IC(50) 50 values equal to (-6)M in mouse macrophages, human leukocytes, and Be Sal osteofibrolytic cells. In these same cell lines, the agents blocked prostaglandin cyclooxygenase activity with IC(50) values of (-6)M. In mouse macrophage and human leukocytes, 5' lipoxygenase activity was also inhibited by the boron derivatives with IC(50) values of 10(-6)M. These IC(50) values for inhibition of these enzyme activities are consistent with published values of known anti-inflammatory agents which target these enzymes.     

邻杂环(噁二唑)甲酰苯胺类化合物的设计合成及杀虫活性初步研究

以超高效杀虫剂氯虫苯甲酰胺为先导,在酰胺部分引入了邻杂环(噁二唑),设计并合成了16个含邻杂环(噁二唑)甲酰苯胺类新化合物。生测结果表明,化合物普遍具有高杀虫活性,在10 mg/L剂量下对小菜蛾的致死率均大于80%。本研究结果为该类化合物的创制提供了参考。     

Structure Determination and Anti-Inflammatory Activity of some Purine Complexes

Organomercury(II)-purine derivatives of the type, p-MeOC(6)H(4)HgL(1) (I), p-NO(2)C(6)H(4)HgCl(L(2))(II), p-MeC(6)H(4)HgCl(L(3))(III) and p-NO(2)C(6)H(4)HgCl(L(3))(IV) [ HL(1) = theophylline, L(2) = theobromine, L(3) = caffeine] have been synthesised and characterised on the basis of spectral studies (IR, UV, (1)H & (13)C NMR). The complexes have been screened for anti-inflammatory activity.     

Bimetallic platinum complexes containing linear tetraphosphine ligands

The meso and rac forms of the tetraphosphine ligand bis[(diphenylphosphinoethyl)phenylphosphino]methane, Ph₂PCH₂CH₂PPhCH₂PPhCH₂CH₂PPh₂ (DPPEPM), have been separated and found to react with 2 equiv of [PtCl₂(cod)] or [PtMe₂(cod)] to generate bimetallic complexes of the form [Pt₂X₄(μ-DPPEPM)]. When [PtClMe(cod)] is treated with the tetraphosphine followed by TlPF₆, the chloride-bridged species [Pt₂Me₂(μ-Cl)(μ-DPPEPM)]PF₆ is obtained. The solid state structures of [Pt₂X₄(μ-meso-DPPEPM)] (X=Cl, Me) are reported, along with preliminary studies of some hydrogenation reactions catalyzed by the bimetallic derivatives.     

Synthesis and Pharmacological Evaluation of Fluorinated Quinoxaline-Based κ-Opioid Receptor (KOR) Agonists Designed for PET Studies

κ-Opioid receptors (KORs) play a predominant role in pain alleviation, itching skin diseases, depression and neurodegenerative disorders such as multiple sclerosis. Therefore, imaging of KOR by a fluorinated PET tracer was envisaged. Two strategies were followed to introduce a F atom into the very potent class of cis,trans-configured perhydroquinoxalines. Whereas the synthesis of fluoroethyltriazole 2 has already been reported, fluoropyrrolidines 14 (1-[2-(3,4-dichlorophenyl)acetyl]-8-[(R)-3-fluoropyrrolidin-1-yl]-perhydroquinoxalines) were prepared by S_N2 substitution of a cyclic sulfuric acid derivative with hydroxypyrrolidine and subsequent transformation of the OH moiety into a F substituent. Fluoropyrrolidines 14 showed similar low-nanomolar KOR affinity and selectivity to the corresponding pyrrolidines, but the corresponding alcohols were slightly less active. In the cAMP and β-arrestin assay, 14b (proton at the 4-position) exhibited similar KOR agonistic activity as U-50,488. The fluoro derivatives 14b and 14c (CO₂CH₃ at the 4-position) revealed KOR-mediated anti-inflammatory activity as CD11c and the IFN-γ production were reduced significantly in mouse and human dendritic cells. Compounds 14b and 14-c also displayed anti-inflammatory and immunomodulatory activity in mouse and human T cells. The PET tracer [¹⁸F]- 2 was prepared by 1,3-dipolar cycloaddition. In vivo, [¹⁸F]- 2 did not label KOR due to very fast elimination kinetics. Nucleophilic substitution of a mesylate precursor provided [¹⁸F]- 14c . Unfortunately, defluorination of [¹⁸F]- 14c occurred in vivo, which was analyzed in detail by in vitro studies.     

Flexible Etherified and Esterified Triphenylethylene Derivatives and Their Evaluation on ER-positive and Triple-Negative Breast Cancer Cell Lines

Tamoxifen (TAM) is a selective estrogen receptor modulator (SERM) with potential clinical benefits for all stages of breast cancer. TAM is primarily metabolized to more potent metabolites via polymorphic CYP2D6. This affects the clinical outcome of TAM treatment. Herein we report novel TAM analogues that can avoid metabolism via CYP2D6. The novel analogues bear a flexible skeleton. Compounds have either an ester group on ring C or homodiaminoalkoxy groups on rings B and C . Compound 6 (E/Z-4-[1-[4-(2-diethylaminoethoxy)phenyl]-3-(4-methoxyphenyl)-2-methyl[propenyl]phenol) was found to be ten-fold more potent than TAM on MCF-7 cells (GI₅₀=0.15 μM). It showed fivefold greater inhibitory activity on MDA-MB-231 cells than TAM (GI₅₀=1.71 μM). Compound 13 (4-{3,3-bis-[4-(3-dimethylaminopropoxy)phenyl]-2-methylallyl}methoxybenzene) was the most potent among the homodiaminoalkoxy derivatives (GI₅₀=0.44) on both MCF-7 and MDA-MB-231 cell lines, respectively. Furthermore, the COMPARE algorithm suggested that it has different molecular targets from those of some other reported anticancer drugs.